

Cited in: *EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

Reviews

- Inhibition of the Hedgehog pathway in lung cancer** 56
A. Dimou (USA), A. Bamias, H. Gogas, K. Syrigos (Greece)

Original Research Articles

- Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody** 4
M. Saiki, T. Yoshizawa, Y. Dotsu, R. Ariyasu, J. Koyama, T. Sonoda, K. Uchibori, S. Nishikawa, S. Kitazono, N. Yanagitani, A. Horiike, M. Nishio (Japan)
- First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials** 10
M. Schuler (Germany), L. Paz-Ares (Spain), L.V. Sequist (USA), V. Hirsh (Canada), K.H. Lee (South Korea), Y.-L. Wu, S. Lu, C. Zhou, J. Feng (China), S.H. Ellis (UK), C.H. Samuelsen (Germany), W. Tang (USA), A. Märten (Germany), E. Ehrnrooth (Denmark), K. Park (South Korea), J.C.-H. Yang (Taiwan)
- Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study** 23
L. Xu, Q. Qi, Y. Zhang, J. Cui, R. Liu, Y. Li (China)
- Real-world lung cancer screening decision-making: Barriers and facilitators** 32
M. Lowenstein, M. Vijayaraghavan, N.J. Burke, L. Karliner, S. Wang, M. Peters, A. Lozano, C.P. Kaplan (USA)
- Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy** 38
A. Sakin, S. Sahin, N. Yasar, C. Demir, S. Arici, C. Geredeli, S. Cihan (Turkey)
- Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219** 48
B. Melosky, P. Bradbury, D. Tu, M. Florescu, A. Reiman, G. Nicholas, N. Basappa, J. Rothenstein, J.R. Goffin, S.A. Laurie, P. Wheatley-Price, N. Leighl, G. Goss, M.N. Reaume, C. Butts, N. Murray, C. Card, J. Ko, N. Blais, S. Gray, H. Lui, P. Brown-Walker, P. Kaurah, L.M. Prentice, L. Seymour (Canada)
- Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials** 62
A. Morabito, M.C. Piccirillo, P. Maione, A. Luciani, L. Cavanna, L. Bonanno, V. Filipazzi, S. Leo, S. Cinieri, F. Morgillo, M.A. Burgio, D. Ferrara, F. Rosetti, R. Bianco, F. Artioli, D. Cortinovis, V. Gebbia, V. Fregoni, M. Mencoboni, C. Sandomenico, A. Rossi, A. Montanino, A. Manzo, G. Rocco, L. Arenare, G. Daniele, S. Signoriello, C. Gallo, F. Perrone, C. Gridelli (Italy)
- c-MET as a biomarker in patients with surgically resected non-small cell lung cancer** 69
G. Tsakonas, J. Botling, P. Micke (Sweden), C. Rivard (USA), L. LaFleur, J. Mattsson (Sweden), T. Boyle, F.R. Hirsch (USA), S. Ekman (Sweden)

(Contents continued overleaf)



Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients	
X. Li, C. Zhang, Z. Sun, F. Yang, R. Xiao, X. Sui, G. Jiang, W. Zhong, J. Wang (China)	75
MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells	
M. Tada, T. Sumi, Y. Tanaka, S. Hirai, M. Yamaguchi, M. Miyajima, T. Niki, H. Takahashi, A. Watanabe, Y. Sakuma (Japan)	88
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis	
M.M. Awad, G.C. Leonardi, S. Kravets, S.E. Dahlberg, A. Drilon, S.A. Noonan, D.R. Camidge, S.-H.I. Ou, D.B. Costa, S.M. Gadgeel, C.E. Steuer, P.M. Forde, V.W. Zhu, Y. Fukuda, J.W. Clark, P.A. Jänne (USA), T. Mok (China), L.M. Sholl, R.S. Heist (USA)	96
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	
S.-K. Liang, J.-C. Ko, J.C.-H. Yang, J.-Y. Shih (Taiwan)	103
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice	
D. Ksienski, E.S. Wai, N. Croteau, A.T. Freeman, A. Chan, L. Fiorino, E.G. Brooks, Z. Poonja, D. Fenton, G. Geller, S. Irons, M. Lesperance (Canada)	110
Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer	
L. Romero-Vielva, S. Viteri, I. Moya-Horno, J.I. Toscas, J.A. Maestre-Alcácer, S. Ramón y Cajal, R. Rosell (Spain)	117
Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups	
S. Tsim, S. Paterson, D. Cartwright, C.J. Fong, L. Alexander, C. Kelly, J. Holme, M. Evison, K.G. Blyth (UK)	123
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer	
J.H.R.J. Degens, K.J.C. Sanders, E.E.C. de Jong, H.J.M. Groen, E.F. Smit, J.G. Aerts, A.M.W.J.. Schols, A.-M. Dingemans (the Netherlands)	130
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio	
A. Shinde, Z.D. Horne, R. Li, S. Glaser, E. Massarelli, M. Koczywas, L. Erhunmwunsee, K.L. Reckamp, B. Weksler, R. Salgia, S. Beriwal, A. Amini (USA)	136
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes	
J.V. Aredo, S.K. Padda, C.A. Kunder, S.S. Han, J.W. Neal, J.B. Shrager, H.A. Wakelee (USA)	144
<i>Short Communications</i>	
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial	
S. Peters (Switzerland), E. Felip (Spain), U. Dafni (Greece), C. Belka (Germany), M. Guckenberger (Switzerland), A. Irigoyen, E. Nadal (Spain), A. Becker (the Netherlands), H. Vees, M. Pless (Switzerland), A. Martinez-Marti (Spain), A. Tufman (Germany), M. Lambrecht (Belgium), N. Andratschke, A.C. Pignet (Switzerland), M. Kassapian (Greece), H. Roschitzki-Voser, M. Rabaglio-Poretti, R.A. Stahel (Switzerland), J. Vansteenkiste (Belgium), D. De Ruyscher (the Netherlands)	83
<i>Case Reports</i>	
Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis	
E. Gaye, M. Geier, P. Bore, M. Guilloïque, F. Lucia, G. Quéré, S. Gouva, G. Robinet, R. Descourt (France)	1
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma	
R. Riedel, S. Michels, C. Heydt, J. Siemanowski, C. Kobe, A. Bunck, S. Schäfer, R.N. Fischer, M. Scheffler, D.S.Y. Abdulla, L. Nogová, S. Koleczko, S. Merkelbach-Bruse, R. Büttner, J. Wolf (Germany)	20
Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies	
J. Solassol, J.A. Vendrell, R. Senal, P. Audran, F. Leenhardt, X. Quantin (France)	45